PATINA Trial Advances HER2+/ER+ Breast Cancer Treatment

Recent advancements in treating HER2-positive breast cancer have been highlighted through two major clinical trials. The PATINA trial revealed promising results for patients receiving both anti-HER2 and anti-estrogen therapies, suggesting a shift in treatment paradigms by allowing continued anti-estrogen therapy during HER2-targeted treatment. In addition, the ShortHER trial demonstrated significant survival benefits linked to tumor-infiltrating lymphocytes (TILs) in patients undergoing adjuvant therapy, with optimal outcomes varying according to TIL levels. Meanwhile, a Phase III study has commenced for JSKN003, an innovative anti-HER2 antibody-drug conjugate that aims to outperform existing treatments like trastuzumab emtansine in patients with advanced breast cancer. These developments reflect a growing understanding of the complexities within HER2-positive breast cancer treatment, offering hope for improved patient outcomes. The integration of both new therapies and biomarkers in treatment strategies is pivotal for enhancing survival rates in this aggressive cancer subtype.